Becton, Dickinson and Company reports Q2 2026 earnings

What happened: Becton, Dickinson and Company (BD) reported Q2 2026 earnings on [date], beating revenue expectations with $4.7 billion and adjusted EPS of $2.90. Management raised full-year adjusted EPS guidance to $12.52-$12.72, maintaining low-single-digit revenue growth guidance. Growth was broad-based, with 90% of the portfolio delivering mid-single-digit growth, driven by biologic drug delivery, Advanced Patient Monitoring, and Precision Diagnostics.

Market impact: BD's strong performance and raised guidance boosted investor confidence in the medical technology sector. The stock was featured in Jim Cramer's Mad Money recap, highlighting the company's AI integration and broad-based execution. This narrative may drive further interest in other medical technology companies with strong growth prospects, such as Abbott Laboratories and Medtronic.

What to watch next: Investors should monitor BD's Q3 2026 earnings, scheduled for [date], to assess the sustainability of its growth momentum. Additionally, the upcoming FDA decision on BD's new drug-eluting stent, expected in [month], could significantly impact the company's share price and the broader medical device sector.